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SUMMARY
From 1976 to 1980, 275 patients with invasive uterine cervical cancer were
treated at theNorthern IrelandRadiotherapy Centre. Mostpatients had combined
intracavitary and external radiotherapy. Only 26% presented with clinical Stage
I disease; there were more of these patients aged 30-39.
Five-yearsurvival was 68% forStage 1, 48% forStage 2, 16% forStage 3 and
0forStage 4. Survival was betterin the agegroup 30-39 (63 %) than in the age
group 20-29 (18%) and for those histologically graded as squamous (49%)
rather than poorly differentiated (35%). Twelve patients required colostomy.
Comparison of these results with other centres in the United Kingdom and the
USA show that there is still room for improvement particularly in the identi-
fication of early stages of the disease.
INTRODUCTION
For the radiotherapist, cancer of the uterine cervix represents one of the major
anatomical sites where treatment is primarily by radiation, and usually under-
taken with curative intent. This review describes the population of patients in
Northern Ireland and the outcome of treatment over the years 1976 - 80, during
which time it was policy to treat invasive cervical cancer by radiation alone. Only
rarely was radiation combined with surgery. When summarised along with two
previous reports dealing with the years 1953 - 601 and 1968 - 72,2 the practice
of almost three decades is available.
PATIENTS AND METHODS
During the study period 275 new patients were treated at the Northern Ireland
Radiotherapy Centre. For three patients there was inadequate initial document -
ation or early loss to follow-up, and the remaining comments relate to 272
patients. In a small minority, follow-up was completed by use of a specially
designed questionnaire. Staging of disease was by clinical examination, almost
always under anaesthesia, complemented by intravenous pyelogram, according
to the FIGO classification.
With no pretension of systematic histological grading, this study separates those
cancers described simply as squamous or moderately differentiated squamous,
from those specifically described as poorly differentiated, Grade 3, or anaplastic.
The vast majority of patients had combined intracavitary and external radio -
therapy. Intracavitary treatment was according to the Manchester system of
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radium dosage with a central tube and paired lateral vaginal ovoids separated by
a washer. No attempt at individual dosimetry was made, and dose calculations
depend on the assumption of ideal geometrical distribution. In these patients the
radium insertion was of 48 or 60 hours duration, corresponding to approximate
Point A doses of 3OGy and 37Gy respectively. When radiu,m alone was used for
Stage 1 cases, two insertions totalling 120 hours were employed. External pelvic
therapy was delivered on megavoltage equipment (Cobalt 60 or 8MeV linear
accelerator). Practice varied slightly between clinicians but generally involved
treating the whole pelvis by opposed anterior and posterior fields to 4OGy in 20
fractions over four weeks, or using a four-field pelvic box technique to spare the
posterior rectum delivering 4OGy in 13 fractions treating three days per week.
There was no uniform policy as to the order in which external and intracavitary
treatments were applied. Central pelvic shielding during external therapy was
used only occasionally.
RESULTS
Patient numbers and age distribution are given in Table 1. Average annual
numbers were higher in the period 1968-72 but no obvious explanation was
available. There has been no significant change in the age distribution when
compared with the two previous reportsl1 2 and the national figures for 1971.3
The increased incidence of invasive cervical cancer in the youngest age group
reported in the NW Thames region4 was not identified in this report.
TABLE I
Age distribution (per cent) of patients with cancer of the uterine cervLx during
three time periods in Northern Ireland. Figures for England and Wales, and for
the NW Thames region are shown for comparison
England NW Thames
Northern Ireland and Wales region
1953-60' 1968-722 1976.80 19713 1975-784
Patient
numbers 520 408 272 4090 1175
Age group
20-29 0.6% 2.5% 11 4.0% 3.1 % 13.5%
30-39 10.8% 5.6% 27 9.9% 8.8% 21.6%
40-49 28.3% 26.0% 47 17.3% 22.7% 13.6%
50-59 28.1% 31.6% 78 28.7% 28.7% 19.2%
60-69 21.4% 20.5% 70 25.7% 19.8% 17.4%
70+ 10.9% 13.7% 39 14.3% 17.0% 14.3%
In the present study 71 patients had Stage 1 disease, 124 were Stage 2, 67 Stage
3 and 10 Stage 4. There has been a trend towards more patients presenting
as Stage 1, from 17% in 1953-60 through 21% in 1968-72 to 26% in
1976 - 80, but no change in the high proportion presenting as Stage 2 and 3
disease. Within the age groups the stage distribution closely matches the overall
pattern except inthe 30 -39 age group where 16 of27 patients (59%) presented
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as Stage 1 . All the survival statistics given are mature five-year figures represent -
ing patients alive and free from disease. This allows direct comparability with
previous reports. No patient in this study who was alive and disease-free at five
years has subsequently relapsed or died from her disease. Overall, 1 18 of 272
patients (43%) were alive at five years. Results by stage groups are shown in
Table 11.
TABLE II
Five -yearsurvivalfor the group of272 patients diagnosed 1976 - 80, classified
by stage groups
Stage 1 2 3 4 Total
Number of patients 71 124 67 10 272
Died from carcinoma 16 57 53 10
Died from unrelated cause 8 7 3 0
Five-year survivors 47 60 11 0 118
(67.6%) (48.4%) (16.4%) 0 43.3%
For the 71 Stage 1 patients, 71 % of 39 treated by combined therapy, and 67%
of 21 receiving radium alone became long,-term survivors. All three patients who
had pre-operative radium insertions survived as did three out of six patients who
had combined therapy post-operatively. Of the 124 Stage 2 patients, 51 % of
103 patients treated with combined therapy survived five years or more. One
patient treated pre -operatively survived, as did five out ofeight who were suitable
for radium treatment alone, but of 12 patients who were only suitable for external
radiotherapy only two survived five years.
When analysed by age-group, the only improvement over the average results is
in the 30 - 39 group, who had 63% survivors. This relates to the high proportion
ofStage 1 cases in this group. Only two of 11 patients aged 20- 29 survived five
years.
Although the allocation of histological grade was not as consistent as would
be desirable, percentage survival figures are presented in Table 111. There is a
difference in survival forthose reported as squamous and as poorly -differentiated
tumours both overall and in Stage 2. This suggests thatthe histological grade isof
prognostic value.
TABLE 111
Five-year survival by histological type
Histological type Overall Stage I Stage 2
Number of patients 272 71 124
Squamous 80 of 165 34 of 47 40 of 72
(49%)* (72%) (56%)
+
Poorly differentiated 29 of 83 9 of 18 15 of 40
(35%)* (50%) (38%)+
Adenocarcinoma 10 of 24 4of8 5 of 12
Adenocarcinoma (42%) (50%) (42%)
*Chi squared = 5.58, p < 0.05 (with Yates' correction)
+ Chi squared =4.20, p < 0.05 (with Yates' correction)
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The late effects of treatment have been assessed only in those patients surviving
five years, to exclude confusion between treatment-related morbidity and the
symptoms of recurrent or progressive disease. Eighty patients (67%) had
predictable treatment morbidity which had completely settled by their first review
at two months. In 17 (14%) symptoms persisted for up to one year. Fifteen ofthe
survivors (12.6%) suffer at least occasionally from symptoms mainly of rectal
irritation, and seven (5.9%) have a permanent colostomy. Within the entire
group of 272 patients there were five further colostomies in patients who
ultimately died from their disease, giving an overall colostomy rate of 4.4%. Of
the 12 patients requiring colostomy, seven had received the higher intracavitary
dose of 60 hours radium with 4OGy pelvic irradiation, three followed double
intracavitary insertionsandtwohad hadpelvic irradiation bysuboptimal regimens.
FIGURE
Times to relapse and death for 136 patients who died from carcinoma of the
cervix
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For each patient who ultimately died from her disease, the period in months to
failure and to death was recorded. Failure is taken as the time of onset of
symptoms due to recurrent or metastatic disease or the detection at follow-up
examination of such disease. It was not possible to specify whether recurrence
was primarily local, pelvic or metastatic (Figure). The pattern of relapse is
predictable over the first 18 months, with less time to relapse or death with
advancing stage. Beyond that, as each group yields a few late failures, the graphs
tend to merge. Prognostic information can be extracted, for example 80% of
Stage 2 cases, who will ultimately relapse, have done so within one year and are
dead within two years.
DISCUSSION
This report demonstrates the results achieved in routine treatment of cervical
cancer in Northern Ireland. While the five year survival figures bear comparison
with other UK results at the same period of time they undoubtedly fall below
current expectation where the anticipated cure rates would be 80% in Stage 1,
60% in Stage 2 and 30 -40% in Stage 3. The survival times for patients treated
by radiotherapy for several major centres are shown in Table IV.
It would be unrealistic to seek increased cure rates simply by increasing the
radiation dose, which would cause a disproportionately greater increase in
morbidity. Policy changes incorporated in current technique will, it is hoped,
result in a reduced morbidity with no loss of disease control. These changes
©B) The Ulster Medical Society, 1987.
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TABLE IV
Survival comparisons (per cent) forpatients treated by radiotherapy
Stage
12 3 4
Northern Ireland
1953-601 57% 46% 25% 12%
1968 - 722 69% 46% 26%
1976-80 68% 48% 16%
United Kingdom
Royal Marsden 1962 - 70 5 74% 46% 16% 6%
Manchester 1961 - 656 73% 52% 25%
Cardiff Cathetron 1974 - 777 77% 50% 25%
USA
Patterns of Care Outcome Study8
All centres 87% 66% 28%
Major centres 92% 77% 60%
Worldwide9
118 institutions; 26 countries
(1959-63) 77% 56% 32% 9%
include adoption of a manual afterloading system of intracavitary treatment with
caesium 137 in place of radium which allows improved positioning and packing.
A fairly modest Point A dose of 32Gy is given from the intracavitary treatment.
External radiotherapy is given in conventional daily fractions of 2Gy and central
pelvic shielding is used more often during the last quarter of the external
treatment. Ifthese improvements produce lower morbidity levels at no expense in
cure rates, then increased dosage could be applied. Radical hysterectomy has
been revived in the 1980s for selected Stage 1 cases in younger patients, and
results of this operation will require close comparison with conventional radio-
therapy.
The findings indicate that patients treated for this disease in Northern Ireland are
very similar to those in the rest of the UK in terms of age, stage at presentation,
histology and outcome. In the under-30 age group described here, the poor
survival is closely related to relatively advanced stage at presentation and worse
than average histology. A similar poorsurvival in young patients was also noted in
patients treated on the Cathetron at the Middlesex Hospital.'0 Here relapse-free-
survival in the over-35s was 87% compared with only 17% in the under-35s.
Such data adds to the current debate as to how best to screen and treat these
young patients who suffer from what appears to be a particularly aggressive
disease.
The impact on prognosis of the histological grade, despite the absence of any
systematic approach in the Northern Ireland data, suggests that this aspect
should be more closely investigated.
Two major aspects of control failure are seen. First the problem of achieving local
control in bulky Stage 2 and Stage 3 presentations, and the more unpredictable
groupofpatients who can achieve local pelvic control, but whose disease behaves
© The Ulster Medical Society, 1987.
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with a more aggressive metastatic tendency. The first problem can be dealt with,
as most commonly in the USA,"1 by considerable increase in the total pelvic
treatment dose but this will produce major morbidity rates greater than 20%.
Experience in the UK of acute and late complications of such increased dose
render this policy largely unacceptable. The second, or indeed either group,
could theoretically benefit from chemotherapy for bulk reduction or eradication
of occult metastases. Experience with existing agents in advanced or recurrent
disease12 shows that only a minority of patients demonstrate any response and
that very few get a complete response which even then cannot be maintained.
There seems no place at present for the routine incorporation of toxic chemo-
therapy in the primary management of cervical cancer. More productive will be
the enhancement of programmes to detect the disease at its earliest stage to
ensure control by proven local measures.
Patients in this study were treated by Dr B D Burrows, Dr A R Lyons and the late Dr G A Edelstyn. The
author wishes to thank Dr B D Burrows for his encouragement to undertake this project, Professor
W S B Lowry for his helpful criticism, and Miss Anne Wilkie for her patient processing of the
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